Open Access
Long non-coding RNA-derived peptides are immunogenic and drive a potent anti-tumour response
Wojciech Barczak
1
,
Simon Mark Carr
1
,
GENG LIU
1
,
Shonagh Munro
2
,
Annalisa Nicastri
3
,
Lian Li
4
,
Claire Hutchings
4
,
Nicola Ternette
3
,
Paul Klenerman
4
,
2
Argonaut Therapeutics Ltd, Oxford Science Park, Oxford, UK
|
Publication type: Journal Article
Publication date: 2023-02-25
scimago Q1
wos Q1
SJR: 4.761
CiteScore: 23.4
Impact factor: 15.7
ISSN: 20411723
PubMed ID:
36841868
General Chemistry
General Biochemistry, Genetics and Molecular Biology
Multidisciplinary
General Physics and Astronomy
Abstract
Protein arginine methyltransferase (PRMT) 5 is over-expressed in a variety of cancers and the master transcription regulator E2F1 is an important methylation target. We have explored the role of PRMT5 and E2F1 in regulating the non-coding genome and report here a striking effect on long non-coding (lnc) RNA gene expression. Moreover, many MHC class I protein-associated peptides were derived from small open reading frames in the lncRNA genes. Pharmacological inhibition of PRMT5 or adjusting E2F1 levels qualitatively altered the repertoire of lncRNA-derived peptide antigens displayed by tumour cells. When presented to the immune system as either ex vivo-loaded dendritic cells or expressed from a viral vector, lncRNA-derived peptides drove a potent antigen-specific CD8 T lymphocyte response, which translated into a significant delay in tumour growth. Thus, lncRNA genes encode immunogenic peptides that can be deployed as a cancer vaccine.
Found
Nothing found, try to update filter.
Found
Nothing found, try to update filter.
Top-30
Journals
|
1
2
3
4
|
|
|
Frontiers in Immunology
4 publications, 4.21%
|
|
|
bioRxiv
3 publications, 3.16%
|
|
|
Cancer Cell International
3 publications, 3.16%
|
|
|
Journal of Hematology and Oncology
3 publications, 3.16%
|
|
|
Nature Communications
3 publications, 3.16%
|
|
|
Genes and Development
3 publications, 3.16%
|
|
|
Non-coding RNA
2 publications, 2.11%
|
|
|
Cancer Gene Therapy
2 publications, 2.11%
|
|
|
Trends in Genetics
2 publications, 2.11%
|
|
|
Advanced Science
2 publications, 2.11%
|
|
|
Molecular Cancer
2 publications, 2.11%
|
|
|
Science Signaling
1 publication, 1.05%
|
|
|
Current Opinion in Immunology
1 publication, 1.05%
|
|
|
Expert Opinion on Drug Discovery
1 publication, 1.05%
|
|
|
Biomedicines
1 publication, 1.05%
|
|
|
Cardiovascular Research
1 publication, 1.05%
|
|
|
Nature Reviews Clinical Oncology
1 publication, 1.05%
|
|
|
Biomolecules
1 publication, 1.05%
|
|
|
Nature Reviews Genetics
1 publication, 1.05%
|
|
|
Journal of Biomolecular Structure and Dynamics
1 publication, 1.05%
|
|
|
Amino Acids
1 publication, 1.05%
|
|
|
Cell Biochemistry and Function
1 publication, 1.05%
|
|
|
Vaccines
1 publication, 1.05%
|
|
|
Trends in Pharmacological Sciences
1 publication, 1.05%
|
|
|
Blood
1 publication, 1.05%
|
|
|
Molecular Therapy
1 publication, 1.05%
|
|
|
NAR Cancer
1 publication, 1.05%
|
|
|
Science advances
1 publication, 1.05%
|
|
|
Molecular Oncology
1 publication, 1.05%
|
|
|
1
2
3
4
|
Publishers
|
5
10
15
20
25
|
|
|
Springer Nature
23 publications, 24.21%
|
|
|
Elsevier
17 publications, 17.89%
|
|
|
Cold Spring Harbor Laboratory
13 publications, 13.68%
|
|
|
MDPI
8 publications, 8.42%
|
|
|
Frontiers Media S.A.
7 publications, 7.37%
|
|
|
Wiley
7 publications, 7.37%
|
|
|
Taylor & Francis
6 publications, 6.32%
|
|
|
American Association for the Advancement of Science (AAAS)
2 publications, 2.11%
|
|
|
Oxford University Press
2 publications, 2.11%
|
|
|
American Society of Hematology
1 publication, 1.05%
|
|
|
Public Library of Science (PLoS)
1 publication, 1.05%
|
|
|
American Chemical Society (ACS)
1 publication, 1.05%
|
|
|
Proceedings of the National Academy of Sciences (PNAS)
1 publication, 1.05%
|
|
|
SAGE
1 publication, 1.05%
|
|
|
Baishideng Publishing Group
1 publication, 1.05%
|
|
|
Portland Press
1 publication, 1.05%
|
|
|
5
10
15
20
25
|
- We do not take into account publications without a DOI.
- Statistics recalculated weekly.
Are you a researcher?
Create a profile to get free access to personal recommendations for colleagues and new articles.
Metrics
95
Total citations:
95
Citations from 2025:
45
(47.37%)
Cite this
GOST |
RIS |
BibTex
Cite this
GOST
Copy
Barczak W. et al. Long non-coding RNA-derived peptides are immunogenic and drive a potent anti-tumour response // Nature Communications. 2023. Vol. 14. No. 1. 1078
GOST all authors (up to 50)
Copy
Barczak W., Carr S. M., LIU G., Munro S., Nicastri A., Li L., Hutchings C., Ternette N., Klenerman P., Kanapin A., Samsonova A., La Thangue N. B. Long non-coding RNA-derived peptides are immunogenic and drive a potent anti-tumour response // Nature Communications. 2023. Vol. 14. No. 1. 1078
Cite this
RIS
Copy
TY - JOUR
DO - 10.1038/s41467-023-36826-0
UR - https://doi.org/10.1038/s41467-023-36826-0
TI - Long non-coding RNA-derived peptides are immunogenic and drive a potent anti-tumour response
T2 - Nature Communications
AU - Barczak, Wojciech
AU - Carr, Simon Mark
AU - LIU, GENG
AU - Munro, Shonagh
AU - Nicastri, Annalisa
AU - Li, Lian
AU - Hutchings, Claire
AU - Ternette, Nicola
AU - Klenerman, Paul
AU - Kanapin, Alexander
AU - Samsonova, Anastasia
AU - La Thangue, Nick B.
PY - 2023
DA - 2023/02/25
PB - Springer Nature
IS - 1
VL - 14
PMID - 36841868
SN - 2041-1723
ER -
Cite this
BibTex (up to 50 authors)
Copy
@article{2023_Barczak,
author = {Wojciech Barczak and Simon Mark Carr and GENG LIU and Shonagh Munro and Annalisa Nicastri and Lian Li and Claire Hutchings and Nicola Ternette and Paul Klenerman and Alexander Kanapin and Anastasia Samsonova and Nick B. La Thangue},
title = {Long non-coding RNA-derived peptides are immunogenic and drive a potent anti-tumour response},
journal = {Nature Communications},
year = {2023},
volume = {14},
publisher = {Springer Nature},
month = {feb},
url = {https://doi.org/10.1038/s41467-023-36826-0},
number = {1},
pages = {1078},
doi = {10.1038/s41467-023-36826-0}
}